Boehringer Ingelheim and Enara bio companies research «dark antigens»

Dark antigens represent a completely new class of antigens associated with the "dark matter" of the genome – a part of the human genome which is usually not expressed as proteins. These sequences are usually "jammed" in healthy cells, but their activation occurs in malignant ones.

Boehringer Ingelheim and Enara bio companies believe that these dark antigens are excellent targets for targeted therapy, which in turn will attack tumors while leaving healthy cells intact. The technology, patented by Enara bio, will be made available to detect and test new dark antigens in lung and gastrointestinal tumors. Boehringer Ingelheim will be responsible for all preclinical and clinical trials. Enara bio is going to use all found antigens for potential use in cell therapy products.

Source: PHARMA PHORUM